TICKERNERD
Menu
MRNAMRNAHealthcare · Biotechnology

MRNA Stock Forecast: Moderna, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$144
+5.38% on the day

The 23 Wall Street analysts covering Moderna, Inc. hold a median 12-month price target of $125 — -13.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 12 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$57.5B
Ticker Nerd rank
82 / 100
Median analyst target
$125
Analysts covering
23
Revenue$143.0M+4.4% y/y
Operating income−$815.0M
Net income−$782.0M
Free cash flow−$563.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
+137.7%
YTD
+388.2%
1Y
+467.0%
From 52W high
−17.4%
From 52W low
+543.9%
$22
$174
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MRNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Moderna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
93
Accruals
89
Momentum
88
Quality
82
Revisions
78
Volatility
61
Growth
44
Issuance
27
Size
5

Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MRNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MRNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Oct 25Jan 26Apr 26Jul 26MRNAHigh $170Median $125Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
5 Buy16 Hold2 Sell
Low $45Median $125High $170

The green dot is the last close — the median target sits −13.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Sept 2026Rothschild & CoDowngradeSell$40 → $81
28 Aug 2026Argus ResearchUpgradeBuy$180
25 Aug 2026Wolfe ResearchUpgradePeer Perform—
25 Aug 2026Wolfe ResearchUpgradePeer Perform—
24 Aug 2026BarclaysMaintainsEqual-Weight—
24 Aug 2026BarclaysMaintainsEqual-Weight$48 → $125
21 Aug 2026JP MorganMaintainsUnderweight$40 → $77
21 Aug 2026JP MorganMaintainsUnderweight—
20 Aug 2026Goldman SachsMaintainsNeutral$67 → $120
20 Aug 2026Goldman SachsMaintainsNeutral—
20 Aug 2026Morgan StanleyMaintainsEqual-Weight$39 → $89
20 Aug 2026Morgan StanleyMaintainsEqual-Weight—
20 Aug 2026UBSMaintainsNeutral—
20 Aug 2026UBSMaintainsNeutral$50 → $150
19 Aug 2026William BlairUpgradeOutperform—
19 Aug 2026William BlairUpgradeOutperform—
3 Aug 2026CitigroupMaintainsNeutral$41 → $60
3 Aug 2026CitigroupMaintainsNeutral—
21 July 2026Goldman SachsMaintainsNeutral$49 → $67
21 July 2026Goldman SachsMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MRNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Moderna, Inc. returned +467.0% against +17.5% for the S&P 500, dividends included.

MRNA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Oct 25Jan 26Apr 26Jul 26MRNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MRNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
15
Analysts cutting
4
Fundamentals

Moderna, Inc. (MRNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.0×

Cheaper than 30% of US stocks

Price / sales
25.8×

Cheaper than 8% of US stocks

Price / book
8.5×

Cheaper than 11% of US stocks

EV / EBITDA
−24.4×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
2.1%

Higher than 32% of US stocks

Earnings growth (YoY)
4.4%

Higher than 41% of US stocks

Gross margin
35.0%

Higher than 42% of US stocks

Operating margin
−557.9%

Higher than 7% of US stocks

Net margin
−141.4%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−39.0%

Higher than 24% of US stocks

Return on assets
−13.3%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Moderna, Inc. (MRNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Moderna, Inc. has a market value of $57.5B and an enterprise value of $53.6B.

  • Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 2.1% year on year.

  • Net income over the same four quarters: −$3.2B, a −142.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−7.99.

  • Free cash flow in the twelve months to 30 June 2026: −$1.2B.

  • Shares outstanding: 399.0M.

  • Trailing P/E: 25.0×; forward P/E: −32.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Moderna, Inc. employs 4,700 people — $470K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MRNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MRNAModerna, Inc.$57.5B
82
RVMDRevolution Medicines, Inc.$42.5B
40
REGNRegeneron Pharmaceuticals, Inc.$82.1B
93
RPRXRoyalty Pharma plc$33.8B
87
ALNYAlnylam Pharmaceuticals, Inc.$32.9B
50
ROIVRoivant Sciences Ltd.$29.2B
38
INSMInsmed, Inc.$28.3B
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Moderna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MRNA news & analysis

How Cathie Wood's Fund Gave Us A Back Door To Moderna's Breakthrough

Investors Business Daily · 11 Sept 2026neutral

The article discusses how Moderna's volatility made it difficult to trade as a swing trade, and instead suggests that the ARK Genomics Revolution ETF provided a way to manage risk while gaining exposure to Moderna's breakthrough.

Why it matters — MRNA watchers would care because it highlights an alternative investment route to Moderna's potential via an ETF, reflecting concerns about the stock's high volatility.

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

24/7 Wall Street · 11 Sept 2026positive

Moderna shares rallied 8% to $147.37 in Friday morning trading, marking a sharp single-name move on a session when the biotech group was quiet and broader U.S. equities were only modestly higher. The stock's advance stood out while peers BioNTech and Merck remained flat.

Why it matters — A MRNA watcher would care because a strong 8% single-day gain ahead of 2026 amid a flat biotech sector highlights notable momentum for the stock relative to its peers.

Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions

Benzinga · 10 Sept 2026neutral

A Benzinga article highlights recent congressional stock trades, focusing on a lawmaker whose bets involve companies tied to Elon Musk and Warren Buffett. The piece frames these trades as a point of interest for retail investors monitoring Congress.

Why it matters — The item does not mention Moderna or make any specific reference relevant to MRNA investors, so it carries no direct significance for a Moderna watcher.

Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 10 Sept 2026neutral

A Motley Fool article compares Amgen and Moderna as potential healthcare investments in 2026. It notes that Amgen has strong profitability and a diverse portfolio of established chronic disease treatments, while Moderna continues transitioning its business from pandemic products to a broader mRNA pipeline.

Why it matters — The piece highlights Moderna's ongoing strategic pivot from COVID-era products to its wider mRNA pipeline, which is central to the company's long-term growth outlook.

AI & Robotics in 2026: 16 Recent Developments for Investors

ETF Trends · 9 Sept 2026neutral

The article reviews 16 recent developments in AI and robotics from August, covering longer-running agents, faster and cheaper inference, AI systems working in laboratories and with physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure for commercial deployment.

Why it matters — MRNA watchers may find relevance because AI systems reaching into laboratories could point to broader industry trends in research automation, though the piece does not mention Moderna.

FAQ

Frequently asked questions about MRNA stock

What is the MRNA stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Moderna, Inc. have a median 12-month price target of $125, with estimates ranging from $45 to $170. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MRNA stock a buy right now?

Of the 23 analysts covering Moderna, Inc., 5 rate it a Buy, 16 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Moderna, Inc. 82 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MRNA?

As at 12 Sept 2026, Moderna, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).

Will MRNA stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies -13.2% from the last close, and Ticker Nerd's factor model ranks Moderna, Inc. 82 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MRNA stock forecast for 2030?

No analyst covering Moderna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $170 over the next 12 months.

How has MRNA stock performed over the past year?

Moderna, Inc. returned +467.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Moderna, Inc. do?

Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology.

What is the latest news on MRNA?

The most recent item we track (Investors Business Daily, 11 Sept 2026): "How Cathie Wood's Fund Gave Us A Back Door To Moderna's Breakthrough". The article discusses how Moderna's volatility made it difficult to trade as a swing trade, and instead suggests that the ARK Genomics Revolution ETF provided a way to manage risk while gaining exposure to Moderna's breakthrough.

Company

About Moderna, Inc.

Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.

CEO Mr. Stéphane Bancel M.B.A. · 4,700 employees · United States · https://www.modernatx.com